Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis

There is currently no therapy impacting the course of amyotrophic lateral sclerosis (ALS). The only approved treatments are riluzole and edaravone, but their efficacy is modest and short‐lasting, highlighting the need for innovative therapies. We previously demonstrated the ability of PXT864, a comb...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Neurosci Res
Huvudupphovsmän: Boussicault, Lydie, Laffaire, Julien, Schmitt, Peter, Rinaudo, Philippe, Callizot, Noëlle, Nabirotchkin, Serguei, Hajj, Rodolphe, Cohen, Daniel
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2020
Ämnen:
Research Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7693228/
https://ncbi.nlm.nih.gov/pubmed/32815196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jnr.24714
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk